Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

To evaluate the efficacy and safety of biological therapy as treatment of Behcet's disease

Next Previous
Trial Profile

To evaluate the efficacy and safety of biological therapy as treatment of Behcet's disease

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 21 Feb 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Adalimumab (Primary) ; Etanercept (Primary) ; Golimumab (Primary) ; Infliximab (Primary) ; Tocilizumab (Primary)
  • Indications Behcet's syndrome
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 15 Feb 2022 Results (n=41) from this study and other studies assessing efficacy and safety of biologic therapy in Behcet's-syndrome refractory to glucocorticoids and at least one conventional immunosuppressive drug, published in the Rheumatology
  • 09 Nov 2021 Results presented at the ACR Convergence 2021
  • 05 Jun 2021 Results (N=42) presented at the 22nd Annual Congress of the European League Against Rheumatism

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top